Ketamine was introduced into clinical practice in the 1960s and continues to be both
clinically useful and scientifically fascinating. With considerably diverse molecular targets …

Ketamine, a versatile anesthetic agent with a complex pharmacological profile, has been
utilized in clinical practice for decades3. This review examines the diverse mechanisms of …

Ketamine, a nonselective NMDA receptor antagonist, is used widely in medicine as an
anesthetic agent. However, ketamine's mechanisms of action lead to widespread …

Ketamine, a racemic mixture consisting of (S)-and (R)-ketamine, has been in clinical use
since 1970. Although best characterized for its dissociative anesthetic properties, ketamine …

This manuscript reviews the clinical evidence regarding single-dose intravenous (IV)
administration of the novel glutamatergic modulator racemic (R, S)-ketamine (hereafter …

Abstract Purpose of Review While ketamine's analgesia has mostly been attributed to
antagonism of N-methyl-d-aspartate receptors, evidence suggests multiple other pathways …

Treating major depression is a medical need that remains unmet by monoaminergic
therapeutic strategies that commonly fail to achieve symptom remission. A breakthrough in …

Major depressive disorder (MDD) is a debilitating illness with significant morbidity and
mortality, leading to attempted and completed suicides. It affects interpersonal relationships …

Ketamine is a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor
which also interacts with various other receptors that account for its myriad actions …

Ketamine (Ket) was developed in 1962 as a less hallucinogenic and shorter acting agent
than phencyclidine. It was given to humans for the first time in 1964. However, Ket produces …